Enzymatica unlocks `The Science That Protects`, an innovative, Penzyme-powered barrier technology that’s clinically proven to break the path to infection, protecting people from upper respiratory viruses.

Investing.com -- Enzymatica AB has named Holger Lembrér as its new Chief Financial Officer, with his start date set for no later than April 2026. Lembrér will join the company’s executive management team. Lembrér brings significant experience as a CFO and finance executive from international and publicly listed companies, primarily in the MedTech, Pharma and industrial sectors. He most recently worked as CFO at Boule Diagnostics, where he managed the Group’s finance function. Before joining Boule Diagnostics, Lembrér served as CFO at Oncopeptides and held various senior positions at ASSA ABLOY, including CFO for the Senior Care business area and Investor Relations Officer at the Group level. He started his career as an auditor at EY. Bengt Baron, Chairman of the Board of Enzymatica AB, said: "Holger combines solid financial expertise with strong business acumen and an international outlook. His experience from growth journeys in listed companies makes him a valuable addition to Enzymatica’s management team, which together with the incoming CEO will drive the company’s international expansion." Lembrér expressed his enthusiasm about joining the company: "I look forward to joining Enzymatica in an exciting phase. The company has significant commercial potential and a dedicated team. Together with the incoming CEO, I aim to help strengthen global commercialization and build sustainable, profitable growth." This article was generated with the support of AI and reviewed by an editor. For more information see our T&C. 3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads. The fastest way to find out is with our Fair Value calculator. We use a mix of 17 proven industry valuation models for maximum accuracy. Get the bottom line for ASSAb plus thousands of other stocks and find your next hidden gem with massive upside.

Jag har funnit en kontraindikator. I grund och botten så fungerar den såhär. När kontraindikation säger "sälj" så köper jag. När kontraindikatorn säger "köp" så

Enzymatica AB's Q3 2025 report highlights significant sales growth in Sweden, with ongoing international expansion efforts and leadership changes.

Enzymatica AB has achieved significant sales growth in Sweden during Q2 2025, while seeking international partnerships to enhance their ColdZyme product.

Enzymatica's Q1 2025 report highlights impressive sales growth in Sweden and the UK, alongside plans for global expansion driven by innovative ColdZyme technology.

Join Enzymatica AB on March 5, 2025, for a digital press briefing revealing breakthrough results from new studies on ColdZyme, enhancing respiratory health.

Enzymatica AB invites media to a digital press briefing presenting results from independent studies on ColdZyme's effects on respiratory health.

Recent independent studies published reveal that ColdZyme significantly reduces respiratory infection symptoms and sick days, targeting the virus directly.

Enzymatica AB's year-end report reveals strong performance in core markets despite challenges, gearing up for expansive international growth in 2025.

Enzymatica treibt nach Führungswechsel die globale Markterschließung voran. Die Überprüfung der Finanzziele und neue Partnerschaften sollen das Wachstum vorantreiben.

LUND, Sweden, July 17, 2025 /PRNewswire/ -- Second quarter Net sales reached SEK 8.3 (6.4) million. The operating result totaled SEK -14.9 (-13.5) million. Earnings per share, basic and diluted, were SEK -0.06 (-0.08). Cash flow from operating activities totaled SEK -21.3 (-19.0) million....

LUND, Sweden, April 29, 2025 /PRNewswire/ -- First quarter Net sales amounted to SEK 12.3 million (9.4). Operating result amounted to SEK -18.0 million (-18.4). Earnings per share, before and after dilution, amounted to SEK -0.07 (-0.11). Cash flow from operating activities amounted to...

STOCKHOLM, Feb. 28, 2025 /PRNewswire/ -- In connection with the publication of results from two independent research studies on ColdZyme, Enzymatica AB invites to a digital press briefing on 5 March 2025. 13:00–14:10 The researchers will present their…

STOCKHOLM, Feb. 28, 2025 /PRNewswire/ -- In connection with the publication of results from two independent research studies on ColdZyme, Enzymatica AB invites to a digital press briefing on 5 March 2025. 13:00–14:10 The researchers will present their…

LUND, Sweden, Feb. 18, 2025 /PRNewswire/ -- Fourth quarter January-December • Net sales reached SEK 17.2 million (15.8). • The operating result totaled SEK -13.7 million (-13.8). • Earnings per share, basic and diluted, were SEK -0.05 (-0.09). • Cash flow…